Mylan News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

28.02.18	Mylan to Bring a Biosimilar of BOTOX to the Market Through a Collaboration and License agreement with Revance Therapeutics (PR Newswire)
28.02.18	Mylan to Present at Raymond James 39th Annual Institutional Investors Conference (PR Newswire)
28.02.18	Mylan to Present at Barclays Global Healthcare Conference (PR Newswire)
26.02.18	Mylan: PTAB Denies Tribe's Motion To Terminate Patent Challenge On Restasis (RTTNews)
26.02.18	16-Year Veteran Director Wendy Cameron to Retire from Mylan N.V. Board after 2018 AGM (PR Newswire)
20.02.18	Mylan Receives Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDA's PEPFAR Program (PR Newswire)
08.02.18	Mylan to Release 2017 Fourth Quarter and Full Year Results and 2018 Guidance on Feb. 28, 2018 (PR Newswire)
01.02.18	Mylan Expands Access to HIV/AIDS Medicines with Launch of First Generic Sustiva® Tablets (PR Newswire)
30.01.18	ARDM Chokes, ABEO On Track, MASI Gets FDA Nod, ALBO Up 50% YTD (RTTNews)
29.01.18	Theravance Biopharma And Mylan Announce FDA Acceptance Of NDA For Revefenacin (RTTNews)
29.01.18	Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease (PR Newswire)
29.01.18	Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease (PR Newswire)
29.01.18	Mylan, Biocon Get Positive CHMP Opinion For Biosimilar Insulin Glargine Semglee (RTTNews)
29.01.18	Mylan and Biocon Receive Positive CHMP Opinion for Semglee™, Biosimilar Insulin Glargine (PR Newswire)
08.01.18	Mylan To Close $1 Bln Share Repurchase Plan (RTTNews)
08.01.18	Mylan to Complete $1 Billion Share Repurchase Plan (PR Newswire)
07.01.18	New Drugs Approved In December (RTTNews)
03.01.18	Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept) (PR Newswire)
29.12.17	Biocon And Mylan's Biosimilar Trastuzumab Gets Approval In Brazil (RTTNews)
29.12.17	Biocon and Mylan's Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through their Partner Libbs (PR Newswire)
20.12.17	Mylan to Present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top (PR Newswire)
14.12.17	Mylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All Claims Against Sanofi's Lantus® Patents (PR Newswire)
11.12.17	BJ's Wholesale Club Announces $10,000 Donation to Dorchester Paws (PR Newswire)
05.12.17	Logic Supply Launches Industrial Fanless NUC With Latest Intel Dawson Canyon Motherboard (PR Newswire)
04.12.17	Mylan To Commercialize Generic Busulfex Injection In U.S. - Quick Facts (RTTNews)
04.12.17	Mylan and Aspen Announce Launch of Generic Busulfex® Injection (PR Newswire)
03.12.17	FDA Okays First Biosimilar For Treatment Of Certain Breast And Stomach Cancers (RTTNews)
01.12.17	U.S. FDA Approves Mylan and Biocon's Ogivri™, the First Biosimilar for Trastuzumab, for the Treatment of HER2-Positive Breast and Gastric Cancers (PR Newswire)
01.12.17	FDA Approval of Heparin Sodium Injection Continues to Demonstrate Mylan's Deep Expertise in Developing Complex Products (PR Newswire)
30.11.17	European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon's Proposed Biosimilars Trastuzumab and Pegfilgrastim (PR Newswire)
29.11.17	Biotech Stocks Facing FDA Decision In December (RTTNews)
20.11.17	Mylan to Present at Evercore ISI Inaugural Biopharma Catalyst/Deep Dive Conference (PR Newswire)
13.11.17	Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease (PR Newswire)
13.11.17	Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease (PR Newswire)
13.11.17	FDA Nod For BMY's Sprycel, ARNA To Report Data In Q1, MYL Delists From TASE (RTTNews)
10.11.17	Mylan Announces Voluntary Delisting from the Tel Aviv Stock Exchange (TASE) (PR Newswire)
09.11.17	Mylan Launches Generic Clolar® for Injection (PR Newswire)
07.11.17	Sponsor and Exhibitor Opportunities Announced for 2018 Emerging Trends in Wellness Conference (PR Newswire)
06.11.17	Mylan Lifts FY17 Earnings Outlook; Says Confident In FY18 View (RTTNews)
06.11.17	Mylan N.V. Earnings Retreat 19% In Q3 (RTTNews)
06.11.17	Mylan Reports Third Quarter 2017 Results and Updates 2017 Guidance (PR Newswire)
02.11.17	NBIX Delivers, MNTA's Biosimilar Drug Trial Fails, No FDA Panel Meet For RARE (RTTNews)
01.11.17	Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting (PR Newswire)
01.11.17	Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting (PR Newswire)
01.11.17	Momenta, Mylan Say M834 Fails To Meet Primary PK Endpoints In Phase 1 Study (RTTNews)
01.11.17	AZN Gets Speedy Nod, RBP-6000 Just One Step Away From Approval, STML Soars (RTTNews)
01.11.17	Mylan President Targeted In Generic Drug Pricing Probe (RTTNews)
28.10.17	Mylan's EpiPen4Schools® Program Surpasses One Million Free Epinephrine Auto-Injector Donations to U.S. Schools (PR Newswire)
27.10.17	The WORKS, the Gourmet Burger Brand that takes burger innovation to the limit…just went even further! (PR Newswire)
26.10.17	Mylan Wins UK Court Ruling Related To Copaxone 40 Mg/mL Patent Against Teva (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone
22.11.24		Pluszeichen in Zürich: SMI zum Ende des Freitagshandels mit grünem Vorzeichen
22.11.24		SIX-Handel: SLI zeigt sich zum Ende des Freitagshandels fester
22.11.24		Deutsche Bank AG: Novartis-Aktie erhält Hold
22.11.24		Freitagshandel in New York: Dow Jones zum Start des Freitagshandels fester
22.11.24		Börse Zürich in Grün: So steht der SMI nachmittags
22.11.24		Freundlicher Handel: SLI klettert am Freitagnachmittag
22.11.24		Pluszeichen in Europa: STOXX 50 notiert im Plus

22.11.24

Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone

22.11.24

Pluszeichen in Zürich: SMI zum Ende des Freitagshandels mit grünem Vorzeichen

22.11.24

SIX-Handel: SLI zeigt sich zum Ende des Freitagshandels fester

22.11.24

Deutsche Bank AG: Novartis-Aktie erhält Hold

22.11.24

Freitagshandel in New York: Dow Jones zum Start des Freitagshandels fester

22.11.24

Börse Zürich in Grün: So steht der SMI nachmittags